Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(13%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
5
63%
Ph phase_3
1
13%
Ph not_applicable
2
25%

Phase Distribution

0

Early Stage

0

Mid Stage

6

Late Stage

Phase Distribution8 total trials
Phase 3Large-scale testing
1(12.5%)
Phase 4Post-market surveillance
5(62.5%)
N/ANon-phased studies
2(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)
Other(4)

Detailed Status

unknown4
Completed2
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (12.5%)
Phase 45 (62.5%)
N/A2 (25.0%)

Trials by Status

unknown450%
withdrawn113%
active_not_recruiting113%
completed225%

Recent Activity

1 active trials
Showing 5 of 8
active_not_recruitingphase_3

Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine

NCT04946734
completedphase_4

Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events

NCT02939872
unknownphase_4

Efficacy of Different Anti-Thrombotic Strategies on the Incidence of Silent Cerebral Embolism After Percutaneous Left Atrial Appendage Occlusion

NCT05671276
unknownphase_4

A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure

NCT03088072
withdrawnnot_applicable

Anticoagulation in Blunt Cerebrovascular Injuries

NCT00494156
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT04946734Phase 3

Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine

Active Not Recruiting
NCT02939872Phase 4

Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events

Completed
NCT05671276Phase 4

Efficacy of Different Anti-Thrombotic Strategies on the Incidence of Silent Cerebral Embolism After Percutaneous Left Atrial Appendage Occlusion

Unknown
NCT03088072Phase 4

A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure

Unknown
NCT00494156Not Applicable

Anticoagulation in Blunt Cerebrovascular Injuries

Withdrawn
NCT00822536Phase 4

Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation

Completed
NCT02224131Phase 4

Study of Antiplatelet Therapy for Intracranial Aneurysm Stent-assisted Coiling

Unknown
NCT01264640Not Applicable

Anti-Platelet Drugs and Brain-derived Neurotrophic Factor (BDNF) in Human Serum and Plasma

Unknown

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8